Document 0128
 DOCN  M9650128
 TI    Immunization with envelope subunit vaccine products elicits neutralizing
       antibodies against laboratory-adapted but not primary isolates of human
       immunodeficiency virus type 1. The National Institute of Allergy and
       Infectious Diseases AIDS Vaccine Evaluation Group.
 DT    9605
 AU    Mascola JR; Snyder SW; Weislow OS; Belay SM; Belshe RB; Schwartz DH;
       Clements ML; Dolin R; Graham BS; Gorse GJ; Keefer MC; McElrath MJ;
       Walker MC; Wagner KF; McNeil JG; McCutchan FE; Burke DS; Division of
       Retrovirology, Walter Reed Army Institute of; Research, Henry M. Jackson
       Foundation for the Advancement of; Military Medicine, Rockville, MD
       20850, USA.
 SO    J Infect Dis. 1996 Feb;173(2):340-8. Unique Identifier : AIDSLINE
       MED/96162091
 AB    Phase I studies of volunteers not infected with human immunodeficiency
       virus type 1 (HIV-1) have shown that immunization with envelope subunit
       vaccine products elicits antibodies that neutralize laboratory-adapted
       (prototype) HIV-1 strains in vitro. Prototype strains are adapted to
       grow in continuous (neoplastic) cell lines and are more susceptible to
       neutralization than are primary isolates cultured in human peripheral
       blood mononuclear cells. In this study, 50 sera from nine phase I
       vaccine trials and 16 from HIV-1-infected persons were evaluated for
       neutralizing antibody activity against 3 laboratory-adapted and 5
       primary HIV-1 isolates. Of 50 sera, 49 neutralized at least 1 of the
       prototype strains; however, none displayed neutralizing activity against
       primary isolates of HIV-1. Serum from most HIV-1-infected persons
       neutralized both laboratory-adapted and primary HIV-1 isolates. These
       data demonstrate a qualitative, or large quantitative, difference in the
       neutralizing antibody response induced by envelope subunit vaccination
       and natural HIV-1 infection.
 DE    Adolescence  Adult  AIDS Vaccines/*ADMINISTRATION & DOSAGE  Cells,
       Cultured  Double-Blind Method  Female  Gene Products, env/*IMMUNOLOGY
       Human  HIV Antibodies/*IMMUNOLOGY  HIV Envelope Protein
       gp120/*IMMUNOLOGY  HIV Infections/*IMMUNOLOGY/VIROLOGY
       HIV-1/*IMMUNOLOGY/ISOLATION & PURIF  *Immunization  Leukocytes,
       Mononuclear/VIROLOGY  Male  Middle Age  Neutralization Tests  Protein
       Precursors/*IMMUNOLOGY  Support, U.S. Gov't, Non-P.H.S.  Support, U.S.
       Gov't, P.H.S.  Virus Cultivation  CLINICAL TRIAL  CLINICAL TRIAL, PHASE
       I  JOURNAL ARTICLE  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).